Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded to “Hold” Rating by Wall Street Zen

Mirum Pharmaceuticals (NASDAQ:MIRM) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also weighed in on MIRM. Leerink Partners reduced their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research report on Thursday. TD Cowen boosted their price target on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the stock a “buy” rating in a report on Thursday. Royal Bank Of Canada lowered their price objective on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $114.92.

Mirum Pharmaceuticals Trading Up 0.1%

Shares of Mirum Pharmaceuticals stock opened at $92.29 on Friday. The firm has a market capitalization of $4.74 billion, a PE ratio of -192.27 and a beta of 0.49. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The firm’s 50 day moving average is $93.40 and its 200 day moving average is $79.08. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.98%. The business’s quarterly revenue was up 49.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.00 EPS. Equities research analysts forecast that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 968 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40. Following the completion of the sale, the senior vice president directly owned 4,503 shares in the company, valued at $465,159.90. This represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $101,288.07. Following the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at $4,207,446.79. This represents a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 45,136 shares of company stock worth $4,352,029. Company insiders own 14.36% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently bought and sold shares of the business. Comerica Bank raised its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC grew its holdings in Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Mirum Pharmaceuticals by 7.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Mirum Pharmaceuticals during the first quarter valued at about $217,000. Finally, Empowered Funds LLC boosted its position in shares of Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares in the last quarter.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.